Cardlytics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Cardlytics de winst en omzet met respectievelijk 81% en 2.2% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 64.6% per jaar.

Belangrijke informatie

81.0%

Groei van de winst

64.6%

Groei van de winst per aandeel

Media winstgroei	13.5%
Inkomstengroei	2.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Nov 05

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Oct 15

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Sep 17

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Aug 09

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Jul 02

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

May 31

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Apr 17

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Mar 03

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Jan 10

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Oct 12

Cardlytics: 6 Bear Cases To Consider

Oct 10

Winst- en omzetgroeiprognoses

NasdaqGM:CDLX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	294	N/A	N/A	7	1
12/31/2025	277	-76	3	3	6
12/31/2024	268	-198	-166	-148	6
9/30/2024	293	-275	-27	-9	N/A
6/30/2024	305	-153	-26	-9	N/A
3/31/2024	312	-173	-22	-8	N/A
12/31/2023	309	-135	-13	0	N/A
9/30/2023	303	-412	-28	-16	N/A
6/30/2023	296	-382	-44	-32	N/A
3/31/2023	295	-485	-58	-44	N/A
12/31/2022	299	-465	-67	-54	N/A
9/30/2022	306	-99	-55	-41	N/A
6/30/2022	298	-150	-51	-37	N/A
3/31/2022	282	-71	-58	-46	N/A
12/31/2021	267	-129	-51	-39	N/A
9/30/2021	244	-124	-45	-32	N/A
6/30/2021	225	-94	-40	-27	N/A
3/31/2021	195	-67	-29	-17	N/A
12/31/2020	187	-55	-18	-8	N/A
9/30/2020	189	-45	-20	-9	N/A
6/30/2020	199	-38	-2	7	N/A
3/31/2020	220	-24	-1	10	N/A
12/31/2019	210	-17	0	11	N/A
9/30/2019	189	-32	-7	3	N/A
6/30/2019	167	-33	-20	-9	N/A
3/31/2019	154	-39	-29	-20	N/A
12/31/2018	151	-53	-26	-19	N/A
9/30/2018	142	-46	-25	-20	N/A
6/30/2018	139	-41	N/A	-29	N/A
3/31/2018	136	-33	N/A	-16	N/A
12/31/2017	130	-25	N/A	-22	N/A
9/30/2017	128	-28	N/A	-19	N/A
6/30/2017	127	-51	N/A	-16	N/A
3/31/2017	120	-77	N/A	-26	N/A
12/31/2016	113	-77	N/A	-32	N/A
12/31/2015	78	-42	N/A	-29	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CDLX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CDLX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CDLX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CDLX ( 2.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CDLX ( 2.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CDLX naar verwachting over 3 jaar hoog zal zijn

Cardlytics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Consensus estimates of losses per share improve by 18%

Price target increased by 46% to US$17.00

Recent updates

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?